Vachiramon Vasanop, Rutnin Suthinee, Patcharapojanart Chanikarn, Chittasirinuvat Natthaphon
Division of Dermatology, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.
J Cosmet Dermatol. 2023 Mar;22(3):792-797. doi: 10.1111/jocd.15498. Epub 2022 Nov 14.
Microfocused ultrasound (MFU) and hyaluronic acid (HA) filler injection are increasingly popular aesthetic procedures. HA filler injection is generally recommended after MFU if combined treatment is required in a single visit. However, data regarding the safe and optimal time of MFU treatment after HA injection is still limited. The purpose of this study was to evaluate the degree of HA loss when performing MFU treatment after dermal filler injection.
Fourteen subjects were recruited in this pilot study. HA was injected intradermally on four 2 × 2 cm areas at the abdomen (0.25 ml/site). Site A was served as control whereas site B, C, D were treated with MFU using 1.5 mm transducer at 60 min, Day 14, and Day 28 after the injection, respectively. All experimental sites were biopsied using a 3-mm punch biopsy to evaluate the histopathological profile at baseline and Day 56. Grading of the quantity of retained HA was evaluated by a blinded experienced dermatopathologist.
All 14 subjects completed the study. One subject has been excluded due to the poor quality of histopathologic slides. Seven subjects (53.9%) at site B and 6 subjects (46.2%) at site C had HA loss at Day 56 compared with baseline. The mean HA grading at baseline and Day 56 was 3.7 vs. 2.8 (p < 0.001) at site B and 3.7 vs. 3.0 (p = 0.001) at site C, respectively. There was no statistical difference between the mean HA grading at baseline and Day 56 at site D (3.7 vs. 3.3, p = 0.073). No inflammation or granuloma was observed on Day 56 of the study.
MFU treatment after HA injection appears to be safe. However, some degree of HA loss was observed if MFU treatment was done within 2 weeks after HA injection.
微聚焦超声（MFU）和透明质酸（HA）填充注射是越来越受欢迎的美容手术。如果单次就诊需要联合治疗，通常建议在MFU后进行HA填充注射。然而，关于HA注射后MFU治疗的安全和最佳时间的数据仍然有限。本研究的目的是评估在真皮填充剂注射后进行MFU治疗时HA的流失程度。
本初步研究招募了14名受试者。在腹部四个2×2cm区域皮内注射HA（0.25ml/部位）。A部位作为对照，而B、C、D部位分别在注射后60分钟、第14天和第28天使用1.5mm换能器进行MFU治疗。所有实验部位均使用3mm打孔活检进行活检，以评估基线和第56天的组织病理学特征。由一位经验丰富的皮肤病理学家在不知情的情况下评估保留HA量的分级。
所有14名受试者均完成了研究。一名受试者因组织病理切片质量差而被排除。与基线相比，B部位7名受试者（53.9%）和C部位6名受试者（46.2%）在第56天出现HA流失。B部位基线和第56天的平均HA分级分别为3.7对2.8（p<0.001），C部位为3.7对3.0（p=0.001）。D部位基线和第56天的平均HA分级之间无统计学差异（3.7对3.3，p=0.073）。在研究的第56天未观察到炎症或肉芽肿。
HA注射后进行MFU治疗似乎是安全的。然而，如果在HA注射后2周内进行MFU治疗，会观察到一定程度的HA流失。
